| Sep 6 |
Cartesian Therapeutics Announces New Employment Inducement Grant
|
| Sep 3 |
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
|
| Aug 8 |
Cartesian Therapeutics GAAP EPS of $0.54, revenue of $33.45M
|
| Aug 8 |
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 7 |
Cartesian Therapeutics Announces New Employment Inducement Grants
|
| Jul 31 |
Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
|
| Jul 2 |
Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
|
| Jul 2 |
Cartesian: Further Value To Be Unlocked After Positive MG Treatment Data
|
| Jul 2 |
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
|
| Jul 2 |
Cartesian posts mid-stage win for lead asset; nabs $130M in financing
|
